Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Carboplatin, Docetaxel, Pertuzumab, Trastuzumab in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved docetaxel in combination with carboplatin, pertuzumab, and trastuzumab for reimbursement as a treatment option for the neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory, or early breast cancer at high risk of recurrence.
This statement is based on a regulatory approval from the Health Service Executive:
Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.